Molecular Biology Research Technique

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

1 week ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy

1 month ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Infrequent, Liver diseases, Primary hyperoxaluria, type I

Gene editing, CRISPR, Rare liver disease, Primary hyperoxaluria type 1 (PH1), Funding

AstraZeneca deepens cell therapy expansion with $1B EsoBiotec buyout

1 month ago talkbio0Tagged Acquisition, AstraZeneca, Autoimmune Diseases, Cell Engineering, Cell Therapy, ENaBL Platform, EsoBiotec, in vivo, Neoplasms

AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases

Roche rolls out new DNA ‘sequencing-by-expansion’ approach

2 months ago talkbio0Tagged DNA, Roche (company)

Roche (company), DNA

Biotech Breakthroughs 2025: Emerging Trends and Technologies Shaping the Industry’s Future

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Cancer Vaccines, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Discovery, Gene Modification, Investments, personalized therapies, Platform technologies, Precision Medicine, solid-state batteries

CRISPR therapeutics, solid-state batteries, precision medicine, AI in drug discovery, gene editing, cancer vaccines, personalized therapies, biotech investment, platform technologies, clinical trial innovation

2025 J.P. Morgan Healthcare Conference: Optimism, Innovation, and Shifting Landscapes

3 months ago talkbio0Tagged Administration occupational activities, ambulatory care services, Aortic Valve Insufficiency, deal activity, digital health, expansion, Gene Modification, Health care facility, Pharmaceutical Services, regulatory environment, Transplant Registry Unified Management Program

AI in healthcare, outpatient care expansion, pharmaceutical services, regulatory environment, deal activity, digital health, gene editing, Trump administration

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

3 months ago talkbio0Tagged Drug Discovery, genetic sequencing, genome sequencing, Genotype, healthcare analytics, Illumina, phenotypic, Precision Medicine, Regeneron, Truveta

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.

Light Horse Therapeutics Secures $1 Billion+ Novartis Collaboration on Launch Day

3 months ago talkbio0Tagged Drug Discovery, Genome Editing, Light Horse, Novartis, Precision - temporal, small molecule therapeutics, strategic collaboration

Light Horse Therapeutics, Novartis, biotech, strategic collaboration, small molecule therapeutics, precision genome editing, drug discovery

Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines

3 months ago talkbio0Tagged cardiometabolic disease, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, epigenetic modification, Gene Modification

Scribe Therapeutics, cardiometabolic disease, CRISPR, gene editing, epigenetic modification, clinical trials, workforce reduction

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

4 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology